AIPT - スカイライン・メディカル (Precision Therapeutics Inc.) スカイライン・メディカル

 AIPTのチャート


 AIPTの企業情報

symbol AIPT
会社名 Precision Therapeutics Inc (スカイライン・メディカル)
分野(sector) Health Care   ヘルスケア
産業(industry) Industrial Specialties  
業種 先端医療機器_テクノロジ―   医療関連(Health Care)
概要 事業概要 Precision Therapeutics Inc. formerly Skyline Medical Inc. is a medical device company that develops and manufactures The STREAMWAY System a solution for the collection and disposal of infectious fluids that result from surgical procedures and post-operative care. The Company distributes these products to hospitals surgical centers and other medical facilities where bodily and irrigation fluids produced during surgical procedures must be contained measured documented and disposed. The Company also manufactures and sells two disposable products required for system operation: a bifurcated single procedure filter and tissue trap and a single use bottle of cleaning solution. Both items are used on a single procedure basis. Its STREAMWAY Automated Surgical Fluid Waste Management System (FMS) is a wall mounted automated system that disposes of an unlimited amount of suctioned fluid from the patient using standard surgical tubing.   スカイライン・メディカルは米国の医療機器メ―カ―。主に、外科手術時や手術後における伝染物質を含む体液などを収集し処理するシステムを製造する。同社が特許を所有する「ストリ―ムウエイ」体液管理システムは、手術に使用される管から体液を吸引し容量を計測、使い捨てフィルタ―で収集し安全に廃棄する。本社はミネソタ州。   Precision Therapeutics, Inc. engages in the manufacture and distribution of healthcare products, and provision of related services. The company offers STREAMWAY System, which is an automated system for the collection and disposal of infectious fluids from surgical and other medical procedures. It operates through the Medical Device and Consumable Products segments. The company was founded by Lawrence W. Gadbaw, Peter L. Morawetz, and Jeffrey K. Drogue on April 23, 2002 and is headquartered in Eagan, MN.
本社所在地 2915 Commers Drive Suite 900 Eagan MN 55121 USA
代表者氏名 Carl Schwartz カールシュワルツ
代表者役職名 President Chief Executive Officer Director 社長兼最高経営責任者(CEO)
電話番号 +1 651-389-4800
設立年月日 37347
市場名 NASDAQ Small Cap
ipoyear ―年
従業員数
url www.skylinemedical.com
nasdaq_url https://www.nasdaq.com/symbol/aipt
adr_tso
EBITDA EBITDA(百万ドル) -6.95743
終値(lastsale) 0.99
時価総額(marketcap) 13264355.61
時価総額 時価総額(百万ドル) 11.35509
売上高 売上高(百万ドル) 1.14303
企業価値(EV) 企業価値(EV)(百万ドル) 10.35161
当期純利益 当期純利益(百万ドル) -7.99458
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Precision Therapeutics Inc revenues increased from $282K to $770K. Net loss increased 6% to $4.1M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Sales and marketing expense increase from $379K to $1.1M (expense) Operations expense increase of 74% to $666K (expense).

 AIPTのテクニカル分析


 AIPTのニュース

   The Daily Biotech Pulse: Axovant Doses First Patient In Gene Therapy Trial, Agile Resubmits NDA, ADMA Prices Offering  2019/05/17 12:03:47 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on May 16) Adverum Biotechnologies Inc (NASDAQ: ADVM )(announced lifting of FDA's partial clinical hold on the second cohort of Phase 1 study of its wet age-related macular degeneration drug) Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN ) Axsome Therapeutics Inc (NASDAQ: AXSM ) Fate Therapeutics Inc (NASDAQ: FATE ) Global Blood Therapeutics Inc (NASDAQ: GBT ) Masimo Corporation (NASDAQ: MASI )(received FDA nod for Radius PPG, a tetherless sensor solution) MediciNova, Inc. (NASDAQ: MNOV ) MeiraGTx Holdings PLC (NASDAQ: MGTX ) TransMedics Group Inc (NASDAQ: TMDX ) Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE ) Down In The Dumps (Biotech stocks hitting 52-week lows on May 16) Auris Medical Holding Ltd (NASDAQ: EARS ) CELLECT BIOTECH/S ADR (NASDAQ: APOP )(announced exploration of strategic alternatives) Enochian Biosciences Inc (NASDAQ: ENOB ) NGM Biopharmaceuticals Inc (NASDAQ: NGM ) Nuvectra Corp (NASDAQ: NVTR )(announced departure of COO and CFO) Precision Therapeutics Inc (NASDAQ: AIPT )(reacted to its first-quarter results) Sellas Life Sciences Group Inc (NASDAQ: SLS ) (reacted to its first-quarter results) Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH ) Tonix …
   Precision Therapeutics Inc. (AIPT) CEO Carl Schwartz on Q1 2019 Results - Earnings Call Transcript  2019/05/16 01:34:08 Seeking Alpha
Precision Therapeutics Inc. (NASDAQ:AIPT) Q1 2019 Earnings Conference Call May 15, 2019 4:30 PM ET Company Participants Scott Gordon - Investor Relations, CORE
   Precision Therapeutics reports Q1 results  2019/05/15 20:10:34 Seeking Alpha
   Precision Therapeutics' Subsidiary TumorGenesis and its Partner 48Hour Discovery Inc. Receive Alberta Innovates Product Demonstration Program Grant to Support Development of Novel Cancer Treatments  2019/04/16 12:45:00 Benzinga
MINNEAPOLIS, April 16, 2019 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT ) ("Precision" or "the Company") today announced that its wholly owned subsidiary, TumorGenesis, is participating with 48Hour Discovery (48HD), a Canadian partner, in receiving a $300,000 CAD grant through the Alberta Innovates Product Demonstration Program. The strategic collaboration will commercialize TumorGenesis' Oncology Discovery Platform Kits, with a set of proprietary reagents from 48HD's core technology to inform personalized treatment decisions in cancer treatments. The development of the TumorGenesis Oncology Discovery Platform Kits will have far-reaching effects around the globe for oncology drug discovery and development of treatments focused around precision medicine. "This grant will provide additional funds to further drive the development of our proprietary Oncology Discovery Technology Platform kits, which will help researchers and clinicians identify which cancer cells bind to which biomarkers," said Richard Gabriel, COO of TumorGenesis, Inc. "These biomarker tags can then be used in the TumorGenesis Oncology Capture Technology Platforms to isolate and help characterize the heterogeneity of the patient's tumor sample." "The TumorGenesis platform and its methodology for tagging a tumor's diverse cancer cell population is highly complementary to our Helomics discovery service business, which utilizes AI (Artificial Intelligence) and tumor genetic and drug response profiling.
   Precision Therapeutics down 9% premarket on equity offering  2019/03/27 13:24:01 Seeking Alpha
   The Daily Biotech Pulse: Axovant Doses First Patient In Gene Therapy Trial, Agile Resubmits NDA, ADMA Prices Offering  2019/05/17 12:03:47 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on May 16) Adverum Biotechnologies Inc (NASDAQ: ADVM )(announced lifting of FDA's partial clinical hold on the second cohort of Phase 1 study of its wet age-related macular degeneration drug) Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN ) Axsome Therapeutics Inc (NASDAQ: AXSM ) Fate Therapeutics Inc (NASDAQ: FATE ) Global Blood Therapeutics Inc (NASDAQ: GBT ) Masimo Corporation (NASDAQ: MASI )(received FDA nod for Radius PPG, a tetherless sensor solution) MediciNova, Inc. (NASDAQ: MNOV ) MeiraGTx Holdings PLC (NASDAQ: MGTX ) TransMedics Group Inc (NASDAQ: TMDX ) Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE ) Down In The Dumps (Biotech stocks hitting 52-week lows on May 16) Auris Medical Holding Ltd (NASDAQ: EARS ) CELLECT BIOTECH/S ADR (NASDAQ: APOP )(announced exploration of strategic alternatives) Enochian Biosciences Inc (NASDAQ: ENOB ) NGM Biopharmaceuticals Inc (NASDAQ: NGM ) Nuvectra Corp (NASDAQ: NVTR )(announced departure of COO and CFO) Precision Therapeutics Inc (NASDAQ: AIPT )(reacted to its first-quarter results) Sellas Life Sciences Group Inc (NASDAQ: SLS ) (reacted to its first-quarter results) Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH ) Tonix …
   Precision Therapeutics Inc. (AIPT) CEO Carl Schwartz on Q1 2019 Results - Earnings Call Transcript  2019/05/16 01:34:08 Seeking Alpha
Precision Therapeutics Inc. (NASDAQ:AIPT) Q1 2019 Earnings Conference Call May 15, 2019 4:30 PM ET Company Participants Scott Gordon - Investor Relations, CORE
   Precision Therapeutics reports Q1 results  2019/05/15 20:10:34 Seeking Alpha
   Precision Therapeutics' Subsidiary TumorGenesis and its Partner 48Hour Discovery Inc. Receive Alberta Innovates Product Demonstration Program Grant to Support Development of Novel Cancer Treatments  2019/04/16 12:45:00 Benzinga
MINNEAPOLIS, April 16, 2019 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT ) ("Precision" or "the Company") today announced that its wholly owned subsidiary, TumorGenesis, is participating with 48Hour Discovery (48HD), a Canadian partner, in receiving a $300,000 CAD grant through the Alberta Innovates Product Demonstration Program. The strategic collaboration will commercialize TumorGenesis' Oncology Discovery Platform Kits, with a set of proprietary reagents from 48HD's core technology to inform personalized treatment decisions in cancer treatments. The development of the TumorGenesis Oncology Discovery Platform Kits will have far-reaching effects around the globe for oncology drug discovery and development of treatments focused around precision medicine. "This grant will provide additional funds to further drive the development of our proprietary Oncology Discovery Technology Platform kits, which will help researchers and clinicians identify which cancer cells bind to which biomarkers," said Richard Gabriel, COO of TumorGenesis, Inc. "These biomarker tags can then be used in the TumorGenesis Oncology Capture Technology Platforms to isolate and help characterize the heterogeneity of the patient's tumor sample." "The TumorGenesis platform and its methodology for tagging a tumor's diverse cancer cell population is highly complementary to our Helomics discovery service business, which utilizes AI (Artificial Intelligence) and tumor genetic and drug response profiling.
   Precision Therapeutics down 9% premarket on equity offering  2019/03/27 13:24:01 Seeking Alpha
   The Daily Biotech Pulse: Axovant Doses First Patient In Gene Therapy Trial, Agile Resubmits NDA, ADMA Prices Offering  2019/05/17 12:03:47 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on May 16) Adverum Biotechnologies Inc (NASDAQ: ADVM )(announced lifting of FDA's partial clinical hold on the second cohort of Phase 1 study of its wet age-related macular degeneration drug) Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN ) Axsome Therapeutics Inc (NASDAQ: AXSM ) Fate Therapeutics Inc (NASDAQ: FATE ) Global Blood Therapeutics Inc (NASDAQ: GBT ) Masimo Corporation (NASDAQ: MASI )(received FDA nod for Radius PPG, a tetherless sensor solution) MediciNova, Inc. (NASDAQ: MNOV ) MeiraGTx Holdings PLC (NASDAQ: MGTX ) TransMedics Group Inc (NASDAQ: TMDX ) Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE ) Down In The Dumps (Biotech stocks hitting 52-week lows on May 16) Auris Medical Holding Ltd (NASDAQ: EARS ) CELLECT BIOTECH/S ADR (NASDAQ: APOP )(announced exploration of strategic alternatives) Enochian Biosciences Inc (NASDAQ: ENOB ) NGM Biopharmaceuticals Inc (NASDAQ: NGM ) Nuvectra Corp (NASDAQ: NVTR )(announced departure of COO and CFO) Precision Therapeutics Inc (NASDAQ: AIPT )(reacted to its first-quarter results) Sellas Life Sciences Group Inc (NASDAQ: SLS ) (reacted to its first-quarter results) Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH ) Tonix …
   Precision Therapeutics Inc. (AIPT) CEO Carl Schwartz on Q1 2019 Results - Earnings Call Transcript  2019/05/16 01:34:08 Seeking Alpha
Precision Therapeutics Inc. (NASDAQ:AIPT) Q1 2019 Earnings Conference Call May 15, 2019 4:30 PM ET Company Participants Scott Gordon - Investor Relations, CORE
   Precision Therapeutics reports Q1 results  2019/05/15 20:10:34 Seeking Alpha
   Precision Therapeutics' Subsidiary TumorGenesis and its Partner 48Hour Discovery Inc. Receive Alberta Innovates Product Demonstration Program Grant to Support Development of Novel Cancer Treatments  2019/04/16 12:45:00 Benzinga
MINNEAPOLIS, April 16, 2019 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT ) ("Precision" or "the Company") today announced that its wholly owned subsidiary, TumorGenesis, is participating with 48Hour Discovery (48HD), a Canadian partner, in receiving a $300,000 CAD grant through the Alberta Innovates Product Demonstration Program. The strategic collaboration will commercialize TumorGenesis' Oncology Discovery Platform Kits, with a set of proprietary reagents from 48HD's core technology to inform personalized treatment decisions in cancer treatments. The development of the TumorGenesis Oncology Discovery Platform Kits will have far-reaching effects around the globe for oncology drug discovery and development of treatments focused around precision medicine. "This grant will provide additional funds to further drive the development of our proprietary Oncology Discovery Technology Platform kits, which will help researchers and clinicians identify which cancer cells bind to which biomarkers," said Richard Gabriel, COO of TumorGenesis, Inc. "These biomarker tags can then be used in the TumorGenesis Oncology Capture Technology Platforms to isolate and help characterize the heterogeneity of the patient's tumor sample." "The TumorGenesis platform and its methodology for tagging a tumor's diverse cancer cell population is highly complementary to our Helomics discovery service business, which utilizes AI (Artificial Intelligence) and tumor genetic and drug response profiling.
   Precision Therapeutics down 9% premarket on equity offering  2019/03/27 13:24:01 Seeking Alpha

 関連キーワード  (先端医療機器_テクノロジ― 米国株 スカイライン・メディカル AIPT Precision Therapeutics Inc.)

医療で使われる機器のこと。レントゲン装置やからだの断面を画像化できるMRI(磁気共鳴画像)装置など高機能機器を含め数多くの種類がある。医療現場で使われるため、正確で精密である点などが求められる。医療機器への需要は着実に高まっており、電機メーカーなどからの進出も進んでいる。

 twitter  (公式ツイッターやCEOツイッターなど)